Chimerix — Investor Presentation (December 2022)
34 slides from Chimerix's investor presentation, Dec 9, 2022
Slide 1: Chimerix Corporate Presentation
Chimerix Corporate Presentation
Slide 2: Forward-Looking Statements
2 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward - looking
Slide 3: Investment highlights
3 Investment highlights • Global revenue potential of ~$750m in first indication • Terminal disease with no effective therapeutic options • High unaided awareness within neuro - oncology community • H3 K27M glioma US patent in to 2037, plus potential patent term reinstatement • Ph 2 designed to isol
Slide 4: Deep pipeline across all development stages
4 Collaborators Preclinical Phase 1 Phase 2 Registrational Approved Deep pipeline across all development stages 1 Malignant glioma 2 Adult recurrent H3 K27M - mutant high - grade glioma 3 H3 K27M - mutant glioma 4. Rapidly Emerging Antiviral Drug Development Initiative IND - enabling studies ONC212
Slide 5: ONC201 Phase 2 Efficacy Analysis
ONC201 Phase 2 Efficacy Analysis
Slide 6: H3 K27M mutant diffuse glioma: high unmet need
6 • H3 K27M mutation is predominantly found among diffuse midline gliomas (DMGs) in young adults and children • Frontline radiotherapy remains standard of care with transient benefit; resection often not feasible • DMGs harboring the H3 K27M mutation are WHO Grade IV; historically invariably lethal
Slide 7: Phase 2 efficacy for ONC201 in recurrent H3 K27M DMG
7 • ONC201 monotherapy exhibited durable, clinically meaningful efficacy in recurrent H3 K27M - mutant DMG - Overall Response Rate (ORR) of 30% (95% CI: 18 - 45%) by RANO HGG and/or LGG dual reader BICR - RANO - HGG criteria assessed by dual reader BICR • ORR 20% (95% CI: 10 – 34%) • Median Duration
Slide 8: FDA-aligned criteria for Phase 2 efficacy analysis
8 Objective • To evaluate monotherapy efficacy of ONC201 in recurrent H3 K27M - mutant diffuse midline glioma Eligibility • Age ≥2yo and received ONC201 under studies ONC006, ONC013, ONC014, ONC016, or ONC018 • Diffuse glioma with a known H3 K27M mutation and involvement of a midline structure of th
Slide 9: ONC201 Ph 2 Efficacy Analysis by BICR: waterfall plot
9 • Strict selection criteria to ensure responses attributable to single agent treatment • Responses require both imaging and clinical criteria • Dual reader blinded independent central review (BICR) • Growing consensus that assessment of enhancing and non - enhancing disease (RANO - HGG and RANO -
Slide 10: RANO-HGG responses observed across age groups
10 10 RANO - HGG responses observed across age groups Responses by age group: <18 years: 1/4 (25%) 18 - 40 years: 5/32 (16%) > 40 years: 4/14 (29%) RANO - HGG response of 8 - year - old subject suggests activity in this population ONC201 Ph 2 Efficacy Analysis by BICR in Recurrent H3 K27M - mutant D
Slide 11: RANO HGG response correlation to performance status
11 11 RANO HGG response correlation to performance status (PS) supports early - line trial Predictably, patients with higher PS were more likely to respond to treatment 100: 1/2 (50%) 90: 4/14 (29%) 80: 4/20 (20%) 70: 1/7 (14%) 60: 0/7 (0%) Supports hypothesis that treating earlier in disease course
Slide 12: Clinically meaningful and durable RANO-HGG responses
12 Clinically meaningful and durable RANO - HGG responses SPD=sum of products of perpendicular diameters (target enhancing lesions per BICR) Only patients with measurable target enhancing lesions by BICR at baseline and with post - baseline evaluations are included. Three patients did not have on -
Slide 13: ONC201 Safety
13 Treatment - related Adverse Events, Integrated Safety Data Set, (N=211 glioma patients) 1 Related TEAEs All grades Grade > 3 Any Treatment - related AE 55.5% 11.8% Fatigue 21.8% 2.8% Nausea 20.4% 0 Vomiting 14.2% 0.5% Headache 8.5% 0.5% Lymphocyte count decreased 6.6% 0.5% Decreased appetite 5.7%
Slide 14: RANO responses correspond with survival and clinical benefit
14 All patients RANO HGG Responders RANO HGG and/or LGG Responders N 50 10 15 PFS at 12 months (number of patients censored) 30% 1 90% (0) 67% (2) OS at 24 months (number of patients censored) 2 35% 1 80% (2) 53% (5) Corticosteroids response 3 (number of patients evaluable) 47% (15) 100% (4) 100% (5
Slide 15: Strong rationale for phase 3 success relative to recent GBM trials
15 Experimental Agent Ph2 Design Biomarker Response criteria Confounded by anti - angiogenic pseudo response ORR Duration of response 6 month PFS Approved? ONC201 – Ph2 rDMG Single agent H3 K27M RANO BICR No 20 - 30% 11.2 35% To be determined Temozolomide Single agent - Levin No 5% ? 21% Yes (OS) Be
Slide 16: Multiple unique aspects to ONC201 data support translation to phase 3 success
16 x Used most robust assessment of response (RANO vs RECIST or McDonald or Levine) x Response consistency across distinct imaging assessments (RANO - HGG and RANO - LGG) x Isolation of single agent activity (progression declared, prior therapy washout) x Responses: gradual, durable, multi - focal x
Slide 17: ONC201 Phase 3 ACTION Study Summary
ONC201 Phase 3 ACTION Study Summary
Slide 18: Pivotal Phase 3 ACTION trial design
18 Now enrolling, a randomized, double - blind, placebo - controlled, multicenter international study in 450 newly diagnosed diffuse glioma patients whose tumor harbors an H3 K27M - mutation. Pivotal Phase 3 ACTION trial design 1. Excludes DIPG and spinal tumors • H3 K27M - mutant diffuse glioma 1 •
Slide 19: Design provides multiple paths for success
19 Design provides multiple paths for success Endpoints expected in early 2025 and final data in 2026 Second OS Interim • ~246 events • Success at HR=0.64 Final OS • ~327 events • Success at HR=0.73 PFS by RANO HGG (2) • ~286 events • Success at HR=0.68 1. Overall Survival (OS) 2. Progression - free
Slide 20: Potential to increase ONC201 efficacy with dose schedule
20 20 Potential to increase ONC201 efficacy with dose schedule • Once per week ONC201 dosing effective as monotherapy in Phase 2 studies • Twice per week dosing on two consecutive days expected to increase duration of therapeutic exposure - Increased exposure time can increase glioma sensitivity to
Slide 21: ONC201 Market Opportunity Assessment
ONC201 Market Opportunity Assessment
Slide 22: Potential market opportunity up to ~$750 million
22 • Potential market opportunity up to ~$750 million • U.S. annual incidence of ~2,000 • Patent protection for lead indication into 2037 - potential U.S. patent term extension (up to five years) • Market research - Nearly all midline glioma patients tested for H3 K27M - mutation - ~20% ORR and/or c
Slide 23: ONC201 interim efficacy results in dopamine-secreting tumors outside the brain
23 • Single agent responses in Ph 2 neuroendocrine trial of ONC201 observed in subset (paraganglioma) • Paraganglioma are adrenal - related tumors with elevated DRD2 expression • Five patients have been treated > 1 year • Fewer short - term and potential long - term toxicities than other paraganglio
Slide 24: ONC201 directly engages DRD2 and ClpP
24 • ONC201 can selectively induce apoptosis in cancer cells by altering activity of two proteins • DRD2 antagonism - DRD2 is a G protein - coupled neuroreceptor that regulates Ras signaling - ONC201 antagonizes DRD2, inhibiting Ras signaling pathways • ClpP agonism - ClpP normally degrades misfolde
Slide 25: H3 K27M glioma cell lines exhibit enhanced sensitivity to ONC201
25 H3 K27M glioma cell lines exhibit enhanced sensitivity to ONC201 Lowe et al., Cancers, 2019; Chi et al., Society of Neuro - Oncology, 2017; Kawakibi et al, Society of Neuro - Oncology, 2019; Koschmann et al., Pediatric Society of Neuro - Oncology 2019; Prabhu et al, Clinical Canc er Research, 201
Slide 26: ONC206 and ONC212
ONC206 and ONC212
Slide 27: ONC206: potentially differentiated DRD2 antagonist + ClpP agonist
27 • Focus in current clinical trials on recurrent central nervous system (CNS) cancers • Efficacy in preclinical models of central nervous system and other tumors • Enrolling 2 dose escalation clinical trials for adult and pediatric CNS tumor patients ONC206: potentially differentiated DRD2 antagon
Slide 28: ONC212: GPR132 + ClpP Agonist
28 ONC212: GPR132 + ClpP Agonist • Distinct molecular target (GPR132) and efficacy profile relative to ONC201/ONC206 • Efficacy in preclinical models of advanced cancers • GLP - tox studies ongoing to potentially advance to IND • Partnerships established for early - stage clinical trials with Brown
Slide 29: Legacy antiviral library - CMX521
Legacy antiviral library - CMX521
Slide 30: CMX-521: anti-SARS-CoV-2 preclinical activity
30 • Ribonucleoside analog that is a viral polymerase inhibitor - Inhaled nebulized liquid aerosol formulation; minimal systemic exposure • Monotherapy efficacy in mouse - adapted SARS - CoV - 2 - MA10 model across multiple endpoints - Lung viral titer - Viral RNA parallel viral lung titer (plaque f
Slide 31: Corporate Update
Corporate Update
Slide 32: TEMBEXA deal term summary
32 32 TEMBEXA ® deal term summary Emergent experienced biodefense company collaborating with government agencies to protect public health. Terms summary : $238 million upfront at closing Up to an additional $124 million in potential BARDA procurement milestones 20% royalty on future U.S. gross profi
Slide 33: Financial strength to achieve our objectives
33 Financial strength to achieve our objectives Dollars (millions) Nine Months Ended Sept 30, 2022 Operating R&D (cash) $(44.7) Operating G&A (cash) (12.5) Op Ex (cash) $(57.2) First - Line (1L) H3 K27M - mutant diffuse glioma – The ACTION Study x Trial initiated November 2022 x Interim OS data expe
Slide 34: Chimerix
Chimerix Corporate Presentation